Honokiol

For research use only. Not for therapeutic Use.

  • CAT Number: I003289
  • CAS Number: 35354-74-6
  • Molecular Formula: C₁₈H₁₈O₂
  • Molecular Weight: 266.33
  • Purity: ≥95%
Inquiry Now

Honokiol(Cat No.:I003289)is a natural biphenolic compound derived from the bark of Magnolia species, widely recognized for its diverse pharmacological properties. It exhibits potent antioxidant, anti-inflammatory, and anticancer activities by modulating several signaling pathways, such as NF-κB, PI3K/Akt, and apoptosis pathways. Honokiol has demonstrated effectiveness in inhibiting tumor growth and metastasis in multiple cancer models and also shows neuroprotective effects, making it promising for neurodegenerative disease research. Its antimicrobial properties further highlight its versatility. Honokiol is an important compound in studies on cancer, inflammation, and neurological health.


Catalog Number I003289
CAS Number 35354-74-6
Synonyms

2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol

Molecular Formula C₁₈H₁₈O₂
Purity ≥95%
Target IκB/IKK
Solubility Soluble to 100 mM in DMSO and to 100 mM in ethanol
Storage 3 years -20C powder
IC50 30 uM (DBTRG-05MG cell)
IUPAC Name 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
InChI InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
InChIKey FVYXIJYOAGAUQK-UHFFFAOYSA-N
SMILES C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C
Reference

</br>1:Transcriptomic analysis of Saccharomyces cerevisiae upon honokiol treatment. Zhu X, Zou S, Li Y, Liang Y.Res Microbiol. 2017 May 10. pii: S0923-2508(17)30089-X. doi: 10.1016/j.resmic.2017.04.007. [Epub ahead of print] PMID: 28499955 </br>2:Therapeutic Action of Honokiol on Postoperative Ileus via Downregulation of iNOS Gene Expression. Mihara T, Mikawa S, Kaji N, Endo M, Oikawa T, Tong-Rong J, Ozaki H, Hori M.Inflammation. 2017 May 10. doi: 10.1007/s10753-017-0576-7. [Epub ahead of print] PMID: 28493080 </br>3:Honokiol inhibits ultraviolet radiation-induced immunosuppression through inhibition of ultraviolet-induced inflammation and DNA hypermethylation in mouse skin. Prasad R, Singh T, Katiyar SK.Sci Rep. 2017 May 10;7(1):1657. doi: 10.1038/s41598-017-01774-5. PMID: 28490739 Free PMC Article</br>4:Honokiol Alleviates Hypertrophic Scar by Targeting Transforming Growth Factor-β/Smad2/3 Signaling Pathway. Zhao D, Wang Y, Du C, Shan S, Zhang Y, Du Z, Han D.Front Pharmacol. 2017 Apr 19;8:206. doi: 10.3389/fphar.2017.00206. eCollection 2017. PMID: 28469575 Free PMC Article</br>5:Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ, Leung EL, Liu L.Front Pharmacol. 2017 Apr 11;8:199. doi: 10.3389/fphar.2017.00199. eCollection 2017. PMID: 28443025 Free PMC Article</br>6:Development of a chitosan-based nanoparticle formulation for ophthalmic delivery of honokiol. Deng F, Hu W, Chen H, Tang Y, Zhang L.Curr Drug Deliv. 2017 Apr 19. doi: 10.2174/1567201814666170419113933. [Epub ahead of print] PMID: 28425869 </br>7:Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Pillai VB, Kanwal A, Fang YH, Sharp WW, Samant S, Arbiser J, Gupta MP.Oncotarget. 2017 Mar 11. doi: 10.18632/oncotarget.16133. [Epub ahead of print] PMID: 28423723 Free Article</br>8:Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma. Yang B, Ni X, Chen L, Zhang H, Ren P, Feng Y, Chen Y, Fu S, Wu J.Drug Deliv. 2017 Nov;24(1):660-669. doi: 10.1080/10717544.2017.1303854. PMID: 28368206 </br>9:Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.Breast Cancer Res. 2017 Mar 28;19(1):39. doi: 10.1186/s13058-017-0829-2. No abstract available. PMID: 28351375 Free PMC Article</br>10:Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo. Wang N, Wang Z, Nie S, Song L, He T, Yang S, Yang X, Yi C, Wu Q, Gong C.Int J Nanomedicine. 2017 Feb 23;12:1499-1514. doi: 10.2147/IJN.S124843. eCollection 2017. PMID: 28260895 Free PMC Article

Request a Quote